<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162889">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977782</url>
  </required_header>
  <id_info>
    <org_study_id>CPKC412A2104E1</org_study_id>
    <nct_id>NCT00977782</nct_id>
  </id_info>
  <brief_title>Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3</brief_title>
  <official_title>An Open-label Phase I/II (Proof of Concept) Trial of PKC412 in Patients With Acute Myeloid Leukemia (AML) and Patients With High Risk Myelodysplastic Syndrome (MDS) With Either Wild Type or Mutated FLT3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, and pharmacokinetics in AML and high risk
      MDS patients with either wild type or mutated FLT3 using PKC412 with intra-patient dose
      escalation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate preliminary anti-tumor activity in AML and MDS patients with wild type or mutated FLT3 receiving continuous twice-daily oral dose of either 50 or 100 mg who have not previously received a FLT3 inhibitor.</measure>
    <time_frame>Day 28 of Cycle 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the pharmacodynamic activity of PKC412 on functional FLT3 inhibition in the cells of these patients ex vivo</measure>
    <time_frame>Day 28 of Cycle 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of PKC412 and its metabolites in peripheral blood WBC and saliva in order to assess the total and &quot;free&quot; concentration of PKC412 and its metabolites at two different twice daily orally administered doses of 50 and 100 mg</measure>
    <time_frame>D1, D2, D3 and D8 of Cycle 1 and D1 of each subsequent cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>PKC412 50 mg BID, Wild Type FLT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PKC412 100 mg BID, Wild Type FLT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PKC412 50 mg BID, Mutant Type FLT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PKC412 100 mg BID, Mutant Type FLT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin (PKC412)</intervention_name>
    <arm_group_label>PKC412 50 mg BID, Wild Type FLT3</arm_group_label>
    <arm_group_label>PKC412 100 mg BID, Wild Type FLT3</arm_group_label>
    <arm_group_label>PKC412 50 mg BID, Mutant Type FLT3</arm_group_label>
    <arm_group_label>PKC412 100 mg BID, Mutant Type FLT3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AML who are not candidates for myelosuppressive chemotherapy or AML who
             have relapsed disease or refractory to standard therapy and not likely to require
             cytoreductive therapy within one month, or MDS subtypes RAEB, RAEB-T or CMML

          -  Patients with a wild type or mutated FLT3 documented within 14 days prior to start of
             study who have not previously received a FLT3 inhibitor.

          -  Patients with a WHO performance status of 0 to 2 with a life expectancy of at least 3
             months

        Exclusion Criteria:

          -  Patients who had prior allergenic, syngeneic, or autologous bone marrow transplant or
             stem cell transplant less than 2 months previously.

          -  Female patients who are pregnant or breast feeding or adults of childbearing age not
             employing an effective method of birth control

          -  Concurrent severe and/or uncontrolled medical or psychiatric condition which may
             interfere with the completion of the study

          -  Impairment of GI function or GI disease that may significant alter the absorption of
             PKC412

          -  Patients who had more than 2 prior regimens for their current relapsed or current
             primary refractory disease.

          -  Uncontrolled active infection

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Slon-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 1, 2012</lastchanged_date>
  <firstreceived_date>September 15, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>May 1, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>FLT3</keyword>
  <keyword>midostaurin</keyword>
  <keyword>wild type FLT3</keyword>
  <keyword>mutated FLT3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>4'-N-benzoylstaurosporine</mesh_term>
    <mesh_term>Staurosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
